Intervacc Valuation Multiples

Intervacc Overview

About Intervacc

Intervacc AB is a biotechnology company. It develops new vaccines based on recombinant proteins to meet the increasing need for effective vaccines in animal health care. The company through its subsidiary focuses on diagnostics in the Swedish animal health market and offers bacteriological and mycological analyses on the Swedish market.

Founded

2001

HQ

Employees

15

Website

intervacc.se

Sectors

BiopharmaceuticalsBioTech

Financials (LTM)

Revenue: $3M

EBITDA: ($7M)

EV

$27M

Valuation Multiples

Multiples.vc

Start free trial

Intervacc Financials

Intervacc reported last 12-month revenue of $3M and negative EBITDA of ($7M).

In the same LTM period, Intervacc generated ($343K) in gross profit, ($7M) in EBITDA losses, and had net loss of ($9M).

Intervacc P&L

In the most recent fiscal year, Intervacc reported revenue of $2M and EBITDA of ($7M).

Intervacc expects next 12-month revenue of XXX and NTM EBITDA of XXX

Intervacc Stock Performance

Intervacc has current market cap of $44M, and enterprise value of $27M.

Intervacc's stock price is $0.13.

Intervacc Valuation Multiples

Intervacc trades at 8.9x EV/Revenue multiple, and (3.8x) EV/EBITDA.

Intervacc Financial Valuation Multiples

As of April 19, 2026, Intervacc has market cap of $44M and EV of $27M.

Equity research analysts estimate Intervacc's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Intervacc has a P/E ratio of (5.0x).

Intervacc Margins & Growth Rates

Intervacc's revenue in the last 12 month grew by 118%.

Intervacc's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.5M for the same period.

Intervacc's rule of 40 is (16%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Intervacc's rule of X is 164% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Intervacc Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

Intervacc M&A Activity

Intervacc acquired XXX companies to date.

Last acquisition by Intervacc was on XXXXXXXX, XXXXX. Intervacc acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Intervacc Investment Activity

Intervacc invested in XXX companies to date.

Intervacc made its latest investment on XXXXXXXX, XXXXX. Intervacc invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).